Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Significant Decrease in Short Interest

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 694,600 shares, a drop of 61.6% from the February 13th total of 1,810,000 shares. Based on an average daily volume of 3,830,000 shares, the short-interest ratio is presently 0.2 days. Approximately 4.7% of the shares of the stock are short sold.

Hedge Funds Weigh In On Xilio Therapeutics

A number of large investors have recently modified their holdings of XLO. Geode Capital Management LLC grew its holdings in shares of Xilio Therapeutics by 85.0% during the 3rd quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock valued at $266,000 after purchasing an additional 155,337 shares during the last quarter. Trustees of Columbia University in the City of New York bought a new position in shares of Xilio Therapeutics in the 4th quarter worth approximately $238,000. Balyasny Asset Management L.P. increased its stake in shares of Xilio Therapeutics by 26.0% in the 4th quarter. Balyasny Asset Management L.P. now owns 343,230 shares of the company’s stock worth $328,000 after acquiring an additional 70,744 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Xilio Therapeutics in the 4th quarter worth approximately $48,000. Finally, Aptus Capital Advisors LLC bought a new stake in Xilio Therapeutics during the 4th quarter valued at about $39,000. 54.29% of the stock is owned by hedge funds and other institutional investors.

Xilio Therapeutics Price Performance

XLO opened at $0.83 on Thursday. Xilio Therapeutics has a one year low of $0.58 and a one year high of $1.93. The company has a fifty day moving average price of $0.94 and a 200-day moving average price of $0.94. The firm has a market capitalization of $36.27 million, a P/E ratio of -0.48 and a beta of -0.38.

Xilio Therapeutics (NASDAQ:XLO) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. The company had revenue of $1.72 million during the quarter, compared to analysts’ expectations of $2.26 million. On average, analysts expect that Xilio Therapeutics will post -1.14 earnings per share for the current year.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.